skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Gavilimomab (Code C2621)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Gavilimomab

Definition: A murine IgM monoclonal antibody (MoAb) developed for the potential treatment of graft versus host disease (GvHD). MoAb ABX-CBL recognizes human CD147 antigen, weakly expressed on human leukocytes and up-regulated on activated lymphocytes. This MoAb is capable of neutralizing inflammatory reactions via a complement-dependent cytotoxic mechanism. However, MoAb ABX-CBL does not offer an improvement over antithymocyte globulin in the treatment of acute steroid resistant GVHD.

Label: Gavilimomab

NCI Thesaurus Code: C2621 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0935795  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
anti-CD147 Monoclonal Antibody ABX-CBL
Monoclonal Antibody ABX-CBL

External Source Codes: 
PDQ Closed Trial Search ID 38221
PDQ Open Trial Search ID 38221 (check for NCI PDQ open clinical trial info)
PubMedID Primary Reference 17110457 (see PubMed Primary Reference info)
UMLS CUI C0935795

Other Properties:
     Name Value (qualifiers indented underneath)
code C2621
Legacy_Concept_Name Monoclonal_Antibody_ABX-CBL
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom